Please wait while the formulary information is being retrieved.
BELVIQ XR (LORCASERIN HCL)
- Weight loss management for obese patient (bmi >= 30)
- Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
20 mg tablet,extended release
- 1 tablet (20 mg) by oral route once daily
Weight loss management for obese patient (bmi >= 30)
- 1 tablet (20 mg) by oral route once daily
Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
- 1 tablet (20 mg) by oral route once daily
- None
Contraindicated
- Soltamox
- tamoxifen
Severe
Moderate
- Conzip
- Synapryn
- tramadol
- tramadol-acetaminophen
- tramadol-glucosamine
- Ultracet
- Ultram
- Ultram Er
- Lactating mother
- Neuroleptic malignant syndrome
- Pregnancy
- Serotonin syndrome
Contraindicated
- Depression
- Peyronie's disease
- Priapism
- Suicidal ideation
- Valvular heart disease
Severe
Moderate
- Acute confusion
- Bradycardia
- Hallucinations
- Heart block
- Hyperprolactinemia
- Neutropenic disorder
- Type 2 diabetes mellitus
BELVIQ XR (LORCASERIN HCL)
- Weight loss management for obese patient (bmi >= 30)
- Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
- None
- Back pain
- Constipation
- Cough
- Dizziness
- Fatigue
- Headache disorder
- Hypoglycemic disorder
- Nausea
- Pharyngitis
- Upper respiratory infection
- Xerostomia
More Frequent
Severe
Less Severe
- Depression
- Hypertension
- Leukopenia
- Lymphopenia
- Acute confusion
- Anorexia
- Blurred vision
- Conjunctivitis
- Diarrhea
- Dry eye
- Insomnia
- Myalgias
- Ocular irritation
- Peripheral edema
- Seasonal allergic rhinitis
- Sinusitis
- Skin rash
- Symptoms of anxiety
- Toothache
- Urinary tract infection
- Visual changes
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anemia
- Cataracts
- Hallucinations
- Hypersensitivity drug reaction
- Mitral valve and aortic valve insufficiency
- Neuroleptic malignant syndrome
- Neutropenic disorder
- Priapism
- Serotonin syndrome
- Suicidal ideation
Less Severe
- Bradycardia
- Euphoria
- Hyperprolactinemia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lorcaserin
No safety and efficacy established. Not recommended by manufacturer.
- 1 Day – 18 Years
- No safety and efficacy established. Not recommended by manufacturer.
Lorcaserin
- Severity Level:
1
- Additional Notes: Weight loss is not rec in pregnancy; may have potential adverse fetal effects
Contraindicated
Lorcaserin
Insufficient human data; based on pharmacology, can adversely affect infant
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data; based on pharmacology, can adversely affect infant |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Weight loss management for obese patient (bmi >= 30) | |
E66 | Overweight and obesity |
E66.0 | Obesity due to excess calories |
E66.01 | Morbid (severe) obesity due to excess calories |
E66.09 | Other obesity due to excess calories |
E66.1 | Drug-induced obesity |
E66.2 | Morbid (severe) obesity with alveolar hypoventilation |
E66.8 | Other obesity |
E66.9 | Obesity, unspecified |
Z68.3 | Body mass index (BMi) 30-39, adult |
Z68.30 | Body mass index (BMi) 30.0-30.9, adult |
Z68.31 | Body mass index (BMi) 31.0-31.9, adult |
Z68.32 | Body mass index (BMi) 32.0-32.9, adult |
Z68.33 | Body mass index (BMi) 33.0-33.9, adult |
Z68.34 | Body mass index (BMi) 34.0-34.9, adult |
Z68.35 | Body mass index (BMi) 35.0-35.9, adult |
Z68.36 | Body mass index (BMi) 36.0-36.9, adult |
Z68.37 | Body mass index (BMi) 37.0-37.9, adult |
Z68.38 | Body mass index (BMi) 38.0-38.9, adult |
Z68.39 | Body mass index (BMi) 39.0-39.9, adult |
Z68.4 | Body mass index (BMi) 40 or greater, adult |
Z68.41 | Body mass index (BMi) 40.0-44.9, adult |
Z68.42 | Body mass index (BMi) 45.0-49.9, adult |
Z68.43 | Body mass index (BMi) 50.0-59.9, adult |
Z68.44 | Body mass index (BMi) 60.0-69.9, adult |
Z68.45 | Body mass index (BMi) 70 or greater, adult |
Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity | |
E66.3 | Overweight |
Z68.27 | Body mass index (BMi) 27.0-27.9, adult |
Z68.28 | Body mass index (BMi) 28.0-28.9, adult |
Z68.29 | Body mass index (BMi) 29.0-29.9, adult |
0-9 | A-Z |
---|---|
E66 | Overweight and obesity |
E66.0 | Obesity due to excess calories |
E66.01 | Morbid (severe) obesity due to excess calories |
E66.09 | Other obesity due to excess calories |
E66.1 | Drug-induced obesity |
E66.2 | Morbid (severe) obesity with alveolar hypoventilation |
E66.3 | Overweight |
E66.8 | Other obesity |
E66.9 | Obesity, unspecified |
Z68.27 | Body mass index (BMi) 27.0-27.9, adult |
Z68.28 | Body mass index (BMi) 28.0-28.9, adult |
Z68.29 | Body mass index (BMi) 29.0-29.9, adult |
Z68.3 | Body mass index (BMi) 30-39, adult |
Z68.30 | Body mass index (BMi) 30.0-30.9, adult |
Z68.31 | Body mass index (BMi) 31.0-31.9, adult |
Z68.32 | Body mass index (BMi) 32.0-32.9, adult |
Z68.33 | Body mass index (BMi) 33.0-33.9, adult |
Z68.34 | Body mass index (BMi) 34.0-34.9, adult |
Z68.35 | Body mass index (BMi) 35.0-35.9, adult |
Z68.36 | Body mass index (BMi) 36.0-36.9, adult |
Z68.37 | Body mass index (BMi) 37.0-37.9, adult |
Z68.38 | Body mass index (BMi) 38.0-38.9, adult |
Z68.39 | Body mass index (BMi) 39.0-39.9, adult |
Z68.4 | Body mass index (BMi) 40 or greater, adult |
Z68.41 | Body mass index (BMi) 40.0-44.9, adult |
Z68.42 | Body mass index (BMi) 45.0-49.9, adult |
Z68.43 | Body mass index (BMi) 50.0-59.9, adult |
Z68.44 | Body mass index (BMi) 60.0-69.9, adult |
Z68.45 | Body mass index (BMi) 70 or greater, adult |
Formulary Reference Tool